Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins. J. Virol. 2012, 86(1):128-42.

Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.

Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc. Natl. Acad. Sci. USA 2012; 109:8694-8698.

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EM, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89-93.

Enhanced HIV-1 neutralization by antibody heteroligation.

Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc. Natl. Acad. Sci. 2012, 109(3): 875-80.

Mixed adjuvant formulations reveal a new combination that elicits antibody response comparable to Freund’s adjuvants.

Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau Q, Barnett SW, Heeney JL. Mixed adjuvant formulations reveal a new combination that elicits antibody response comparable to Freund’s adjuvants. PLoS One. 2012, 7(4): e35083.

A mouse model for HIV-1 entry.

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. A mouse model for HIV-1 entry. Proc. Natl. Acad. Sci. 2012, 109(39): 15859-64.

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. J. Virol. 2012, 86(13): 7052-9.

Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors.

Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SFJ, Engelman A, Fuchs JR, Kvaratskhelia M. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012 May 11;287(20):16801-11. doi: 10.1074/jbc.M112.354373. Epub 2012 Mar 21. PubMed PMID: 22437836; PubMed Central PMCID: PMC3351293.

Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys.

Liu J, Li H, Iampietro MJ, Barouch DH. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J. Virol. 2012; 86:7829-7835.

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18(11): 1688-92.